Results from a completed Phase II study with the investigational FLT3 inhibitor, quizartinib (AC220; Astellas Pharma/Ambit Biosciences) as an oral monotherapy treatment regimen in patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) were presented earlier today at the 54th Annual Meeting of the American Society of Hematology (ASH).
The Phase II ACE study recruited patients into two separate cohorts of…Continue
Added by Editorial Team on December 10, 2012 at 4:30pm — No Comments
Final results from a randomized, placebo-controlled, double-blind, phase II clinical trial with the selective MET inhibitor tivantinib (ARQ 197; ArQule, Inc. and Daiichi Sankyo Company, Limited) as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC) shows positive results. The data was presented at the…Continue
Added by Peter Hofland, PhD on June 11, 2012 at 4:00am — No Comments
The latest data on the investigational drug regorafenib (BAY 73-4506)from the Phase III CORRECT trial(Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) were presented at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.
Regorafenib (BAY 73-4506) is an an investigational oral multi-kinase inhibitor developed by Bayer which targets angiogenic,…
Added by Peter Hofland, PhD on January 18, 2012 at 9:30am — No Comments
A new test may help lung cancer patient benefit from early, persoalized treatment option. The cobas EGFR Mutation Test, a real-time polymerase chain reaction-based diagnostic test that identifies 41 mutations across exons 18, 19, 20 and 21 of the EGFR gene using multiplex PCR chemistry developed by Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd, is now CE marked for commercial availability in Europe and other countries…Continue
Added by Peter Hofland, PhD on November 30, 2011 at 11:30pm — No Comments
Added by Peter Hofland, PhD on June 5, 2011 at 2:30pm — No Comments
Added by Peter Hofland, PhD on June 3, 2011 at 12:00pm — No Comments
A combination of three drugs, lapatinib (Tykerb®/Tyverb® , GlaxoSmithKline), an orally active, reversible, small-molecule tyrosine kinase inhibitor that potently inhibits both HER1 and HER2 tyrosine kinase activity, trastuzumab (Herceptin®, Genentech), a humanized monoclonal antibody directed against HER2, and paclitaxel (…Continue
Added by Peter Hofland, PhD on December 10, 2010 at 11:30am — No Comments
Gefitinib (Iressa, Astra Zenca) may be a promising chemoprevention agent for pancreatic cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Gefitinib is in a class of anti-cancer medications called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It works by blocking the action of a certain naturally occurring…
Added by Peter Hofland, PhD on November 8, 2010 at 11:30pm — No Comments
A Phase III study (the DASISION study), has found that after one year, dasatinib (Sprycel), a highly potent BCR-ABL kinase inhibitor, is superior to the standard first-line drug, imatinib (Gleevec), for bringing about cytogenetic and molecular responses in patients newly diagnosed with chronic myeloid leukemia (CML).The study results from this Phase II study, were presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from June 4 -…Continue
Added by Peter Hofland, PhD on June 7, 2010 at 11:30pm — No Comments